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Abstract
Background: In rheumatoid arthritis (RA) macrophages play a major role in amplifying synovial inflammation. Important
activating signals are those induced by Toll-like receptor (TLR) ligands and by activated T cells. The balance between
activating and inhibitory Fc gamma receptors (FccRs) on macrophages might be crucial in modulating these inflammatory
responses. The purpose of this study was to determine FccR expression on pro- and anti-inflammatory macrophages
(gmMQ and mMQ, respectively) and identify functional consequences on immune complex uptake and macrophage
activation.
Methods: Human monocytes were isolated and differentiated into gmMQ and mMQ. A full FccR characterization of both
macrophage subtypes was performed and uptake of fluorescent immune complexes (ICs) was determined. FccRIIb isoforms
were determined by qPCR. Macrophages were stimulated via different TLRs or cytokine activated T cells in the presence or
absence of ICs and cytokine production was determined. Blocking studies were performed to look into the pathways
involved.
Results: mMQ expressed high levels of the activating FccRIIa and FccRIII and low levels of the inhibitory FccRIIb, while the
FccR balance on gmMQ was shifted towards the inhibitory FccRIIb. This was accompanied by a clear increase in FccRIIb1
mRNA expression in gmMQ. This resulted in higher IC uptake by mMQ compared to gmMQ. Furthermore, FccR-mediated
stimulation of gmMQ inhibited TLR2, 3, 4 and 7/8 mediated cytokine production via FccRIIb and PI3K signaling. In addition,
gmMQ but not mMQ produced TNFa upon co-culture with cytokine activated T cells, which was reduced by IC binding to
FccRIIb. The latter was dependent on PI3K signaling and COX2.
Conclusions: FccR expression patterns on gmMQ and mMQ are significantly different, which translates in clear functional
differences further substantiating FccRIIb as an interesting target for inflammation control in RA and other autoimmune/
inflammatory diseases.
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Introduction
One of the major pathways underlying the pathogenesis of
rheumatoid arthritis (RA) is the aberrant production of
inflammatory cytokines by macrophages. In the arthritic joint,
macrophages are one of the main effector cells present and their
levels correlate with disease activity and joint destruction [1,2].
Their levels are mainly associated with inflammatory cytokines
such as TNFa and interleukin (IL) 1b, and could be sustained by
factors like granulocyte-macrophage colony-stimulating factor
(GM-CSF), present in the RA synovial joint [3–5]. Multiple
pathways are proposed to play a role in macrophage activation
in RA. One mechanism inducing cytokine production by RA
macrophages is the triggering of Toll-like receptors (TLRs).
Many endogenous TLR ligands have been found in an arthritic
joint, such as GP96 and SNAPIN, which activate cells via TLR2,
small heat shock protein B8 that can activate TLR4, and self-
RNA from damaged cells which is likely to stimulate macro-
phages via TLR3 or TLR7/8 [6–10]. Blocking antibodies against
these TLRs reduce spontaneous cytokine production by RA
synovial tissue cultures, confirming they are not only present in
the arthritic joint but also contribute to the abundant cytokine
production seen in RA [10–12].
Another pathway mediating synovial macrophage activation is
by direct interaction with activated T cells. Cytokine activated T
cells resemble RA synovial T cells in their contact-dependent
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effector function and activation phenotype [13,14]. These cells can
be cultured from peripheral blood lymphocytes in the presence of
IL-2, IL-6 and TNFa (cytokine activated T cells, Tck) and induce
an unbalanced, inflammatory cytokine response from monocytes
[14].
Another component present in many RA patients are auto-
antibodies. These can form immune complexes (IC) and especially
when deposited in tissues they can activate macrophages. Soluble
ICs can have cell activating but also inhibitory effects, as is
emphasized by IVIg treatment [15]. An important deciding factor
for the cellular response to ICs is the balance of activating and
inhibitory Fc gamma receptors (FccRs).
The FccR system consists of the activating FccRI, FccRIIa and
FccRIII that trigger cell activation via an immunoreceptor
tyrosine-based activation motif (ITAM) in their cytoplasmic
domain and the inhibitory FccRIIb that signals via an immunor-
eceptor tyrosine-based inhibition motif (ITIM) [16]. As the only
inhibitory FccR, FccRIIb is an important brake on the immune
system by inhibition of cell activation via the activating FccRs on a
wide array of cells and inhibition of the B cell receptor. FccRIIb
has two major isoforms, namely FccRIIb1 and FccRIIb2, which
differ in their capabilities to mediate endocytosis and in their
distribution on immune cells [17–20]. FccRIIb1 predominates in
B cells, while FccRIIb2 is the major isoform in myeloid cells. We
and others have previously shown that IC binding to FccRIIb can
also inhibit TLR4 signaling [21,22]. In our previous report, only
RA patients that could control their disease activity without the
need of anti-rheumatic drugs had high FccRIIb levels on their
dendritic cells (DC) and were capable of this inhibition [21]. This
supports an important regulatory role for FccRIIb in controlling
inflammation in RA.
Since proinflammatory macrophages are important in the
pathogenic process in RA and there is no data on the expression
and function of the inhibitory FccR on such macrophages we
aimed to delineate the expression of FccR receptors on
homeostatic M-CSF macrophages (mMQ) and inflammatory
GM-CSF macrophages (gmMQ). We determined the complete
FccR balance on gmMQ and mMQ and tested whether functional
differences were attributed to this. We mainly focused on
combined FccR triggering with macrophage activation via a
range of TLRs implicated in RA pathology or activated T cells
and found that FccRIIb was able to dampen both TLR and Tck
induced TNFa production when this inhibitory FccRIIb was
highly expressed.
Materials and Methods
Ethics statement
The study protocol was approved by the medical ethical
committee of the Radboud university medical center (Nijmegen,
the Netherlands) and the University Medical Center Utrecht
(Utrecht, the Netherlands) and all healthy volunteers gave their
written informed consent. All experiments were performed in
accordance with the Helsinki Declaration.
Culture of monocyte-derived gmMQ and mMQ and Tck
cells
Peripheral blood mononuclear cells were isolated from venous
blood of healthy volunteers using density-gradient centrifugation
over Ficoll (GE Healthcare, Uppsala, Sweden). Monocytes and
CD4+ T cells were obtained using CD14 and CD4 microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). gmMQ and mMQ
were generated by culturing monocytes in the presence of GM-
CSF (800 U/ml; R&D Minneapolis, Minnesota, USA) or macro-
phage colony-stimulating factor (M-CSF, 25 ng/ml; R&D) for 6
days. Macrophages were cultured in 6 well plates (Corning, New
York, USA) with 1,06106 cells per well in 2 ml medium (RPMI-
1640 Dutch modification (Gibco Life Technologies, Grand Island,
New York, USA)) supplemented with 10% FCS, antibiotic-
antimycotic and L-glutamine (Gibco Life Technologies). Culture
medium with the same supplements (1 ml) was added at day 3 and
the cells were harvested at day 6. In parallel, autologous CD4+ T
cells were cultured in complete medium with recombinant human
IL-2 (25 ng/ml), IL-6 (100 ng/ml) and TNFa (25 ng/ml) at
26106 cells/ml for 6 days (all from R&D).
Phenotypical analysis
Using standardized flow cytometry protocols as described
previously gmMQ and mMQ were phenotyped using antibodies
against CD14, CD163 (both BD Biosciences, Franklin Lakes, New
Jersey, USA) and MHC-II DR/DP (clone Q1514) [23]. FccR
expression was determined with antibodies against FccRI (CD64,
PE labeled, clone 10.1; Dako, Glostrup, Denmark), FccRIII
(CD16, PE labeled, clone DJ130c; Dako), clone IV.3 which
preferentially binds to FccRIIa (StemCell Technologies, Vancou-
ver, Canada) and the FccRIIb specific antibody 2B6 (Alexa488
labeled; MacroGenics, Rockville, Maryland, USA). Expression of
unlabeled markers was visualized via a FITC labeled goat-anti-
mouse secondary antibody. Cell fluorescence was measured on a
FACS Calibur (BD) and analyzed using Flowjo software for the
mean fluorescence intensity (MFI) and the proportion of positive
cells relative to cells stained with the appropriate IgG isotypes.
RNA isolation and qPCR
Total RNA was extracted in 0.5 ml of TRI-reagent and treated
with DNase to remove genomic DNA before being reverse-
transcribed into cDNA. qPCR was performed on a Quantstudio
12K Flex (Life Technologies) with SYBR Select Master Mix (Life
Technologies), 7.5 ng cDNA and a primer concentration of
0.5 mM in a total volume of 15 ml. qPCR signals were quantified
by comparing the cycle threshold value (Ct) of the gene of interest
of each sample with the Ct value of the reference gene GAPDH
(DCt). Results were deployed as relative expression (22DCt). The
following primers were used: GAPDH forward ATGGG-
GAAGGTGAAGGTCG, reverse GGGGTCATTGATGGCAA-
CAATA; FccRIIb1 forward GGATTTCAGCTCTCCCAG-
GAT, reverse CGGTTCTGGTCATCAGGCTC; FccRIIb2
forward AAAGCGGATTTCAGCCAATC, reverse CAAGA-
CAATGGAGACTAAATACGGT.
Phagocytosis and binding assay
Phagocytosis assays were performed with fluorescently labeled
ICs, prepared as previously described [24]. Macrophages were
incubated with FITC-labeled ICs (50 mg/ml) for 30 min at 4uC
and 37uC to determine binding and uptake, respectively.
Unattached ICs were washed away before determining binding
and uptake by flow cytometry. To determine IC uptake
extracellular attached FITC-IC was quenched by adding trypan
blue (1/40 diluted in PBS, Sigma-Aldrich) to the samples just
before determining the IC uptake by flow cytometry.
Stimulation of monocyte-derived macrophages
At day 6 macrophages were harvested and plated in a
concentration of 0.56106 cells/ml in 96 well culture plates
(100 ml). Immune complexes used in this study were prepared by
heating human IgG (Sigma-Aldrich, St. Louis, Missouri, USA) in
PBS at 63uC for 30 minutes (heat-aggregated immune complexes
gmMQ Express Functionally High FccRIIb Levels
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(IC)), as previously described [25] and were used in a concentra-
tion of 50 mg/ml. Macrophages were stimulated or not with ICs
for 15–30 minutes before the addition of TLR agonists for 20
hours. The following concentrations of TLR agonists were used:
Pam3CSK4 (5 mg/ml, EMC Microcollections, Tu¨bingen, Ger-
many), Poly(I:C) (25 mg/ml, Invivogen, San Diego, California,
USA), LPS (100 ng/ml, E. coli 0111:B4, Sigma-Aldrich) and
R848 (2 mg/ml, Invivogen) for TLR2/1, 3, 4 and 7/8 respectively.
The LPS was double-purified to remove any contaminating
proteins as described previously [26]. Macrophages were also co-
cultured with cytokine-activated T cells for 20 hours in a 1:5 ratio
in the presence or absence of IC (50 mg/ml) prestimulation for
1 h.
FccRIIb blocking was performed by 30 min incubation of mQ-1
with 10 mg/ml 2B6 antibody (MacroGenics) or an isotype control
at 4uC before stimulation with ICs and LPS or Tck. In other
experiments gmMQ were treated with the PI3K inhibitors
Wortmannin (0.1 mM; Calbiochem, San Diego, California,
USA) or LY294002 (10 mM; Calbiochem) or COX2 inhibitor I
(20 mM; Calbiochem) for 1 h at 37uC before stimulation.
Measurement of cytokines in culture supernatants
Levels of IL-10 and TNFa were measured in the supernatants
using commercially available kits (Millipore, Billerica, Massachu-
setts, USA) according to the manufacturer’s instructions. Cytokine
Figure 1. gmMQ express high FccRIIb levels, while mMQ express more FccRIIa and FccRIII. Monocytes were cultured for 6 days with GM-
CSF or M-CSF into gmMQ and mMQ respectively. Expression of CD14, CD163 and MHC-II (A) and all FccRs (B) was determined by flow cytometry. (B)
For FccR expression, representative FACS plots are shown together with bar graphs showing mean (and SEM of) MFI and percentage of positive cells
from 11 donors. Histograms show isotype control (thin line) and FccR specific antibody (solid grey). (C) mRNA expression of FccRIIb1 and FccRIIb2
were determined by qPCR and plotted as relative expression compared to GAPDH. Bars are mean and SEM of 7 donors. (D) gmMQ and mMQ were
incubated with FITC-labeled ICs (50 mg/ml) for 30 min at 4uC for binding and 37uC for uptake. IC uptake was determined in the presence of trypan
blue. Bars are mean and SEM from 4 donors. *P,0.05, **P,0.01 and ***P,0.001 compared to mQ-1.
doi:10.1371/journal.pone.0110966.g001
gmMQ Express Functionally High FccRIIb Levels
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levels were measured and analyzed with the Bio-Plex system (Bio-
Rad, Hercules, California, USA).
Statistical analysis
Differences were analyzed using paired Student’s t-tests. P
values less than 0.05 were considered significant.
Results
gmMQ express high levels of the inhibitory FccRIIb, while
mMQ express higher levels of the activating FccRIIa and
FccRIII
Monocytes were cultured into pro- and anti-inflammatory
gmMQ and mMQ in the presence of either GM-CSF or M-CSF.
To confirm the phenotype of our gmMQ and mMQ we first
analyzed their expression of CD14, CD163 and MHC-II. In line
with literature the expression of CD14 and CD163 was higher on
mMQ, while MHC-II was increased on gmMQ (Figure 1A) [21].
We further evaluated the expression of activating and inhibitory
FccRs. The monomeric IgG receptor FccRI was similarly
expressed in gmMQ and mMQ, while FccRIII expression was
highly increased on mMQ compared to gmMQ (regarding both
MFI and percentage of positive cells, Figure 1B). Investigating the
activating and inhibiting subtype of FccRII separately, we
observed a marked difference between the gmMQ en mMQ.
Whereas the activating FccRIIa is expressed higher on mMQ,
expression of the inhibitory FccRIIb was increased on gmMQ
(Figure 1B). More specifically, the FccRIIb/FccRIIa ratio was
1.56 for gmMQ and 0.48 for mMQ. Thus, gmMQ display an FccR
balance favored towards the inhibitory subtype whereas the
opposite was found on mMQ. FccR expression was also
determined on gmMQ and mMQ from some RA patients, which
showed a similar FccR distribution compared to healthy controls
(data not shown). In vivo in situations in which GM-CSF is
produced most likely also a basal level of M-CSF will be present.
To determine the effect of the combination of both growth factors
on macrophage development we also cultured macrophages with
GM-CSF and M-CSF. This resulted in a phenotype similar to
gmMQ, suggesting GM-CSF is dominant over M-CSF, at least
regarding FccR expression (data not shown).
We further aimed to differentiate between the two major
FccRIIb isoforms, FccRIIb1 and FccRIIb2. Since the extracellu-
lar domain of these isoforms is the same we used qPCR to
determine the expression of these variants in mMQ and gmMQ.
Using isoform specific primers we found that FccRIIb2 expression
was similar in both macrophage subtypes, while FccRIIb1
expression was significantly increased in gmMQ compared to
mMQ (Figure 1C). gmMQ thus have an increased expression of
the FccRIIb variant usually more predominant in B cells which is
less capable of mediating endocytosis.
The capacity to take up ICs is an important function of
macrophages. To evaluate the functionality of the altered
aforementioned FccR balance, we investigated whether the
gmMQ and mMQ display a different binding and uptake capacity
of ICs. mMQ show a significantly increased potential for both
binding and uptake of ICs compared to gmMQ (Figure 1D). This
is fitting with the enhanced expression of FccRIIa and FccRIII on
mMQ, which have a higher affinity for most IgG isotypes
compared to FccRIIb [27] and the increased expression of the
non-endocytosing FccRIIb1 on gmMQ.
ICs inhibit TLR induced cytokine production by gmMQ
but not by mMQ
To further evaluate the functional consequences of the
differential FccR expression on gmMQ and mMQ and to test
whether ICs can also inhibit TLR4 signaling in human
macrophages that express high FccRIIb levels, gmMQ and
mMQ were stimulated with TLR ligands in combination with
ICs. mMQ and gmMQ were first stimulated with ICs alone to
determine the effect of differential FccR expression on these cells
on IC induced cytokine production. In mMQ ICs induced
significant but low levels of TNFa and IL-10 production, while
there was no clear cytokine induction observed in gmMQ
(Figure 2A). Upon TLR 4 stimulation with LPS gmMQ produced
high levels of TNFa and low levels of IL-10, while mMQ were
marked by their relatively high IL-10 production and low
production of TNFa which corroborates the literature (Figure 2B)
[5,28]. After co-stimulation with ICs, gmMQ were able to
significantly attenuate TNFa production compared to those
stimulated with LPS alone, while IL-10 production was relatively
unaffected (Figure 2B). In contrast, but in line with our
observations on FccR expression, the addition of ICs to LPS did
not result in inhibition of TLR4 mediated cytokine production in
mMQ. In fact, mMQ produced significantly more IL-10 after co-
stimulation with ICs.
To determine if this inhibitory pathway can also affect cytokine
induction by other TLR ligands, similar experiments were
performed with specific ligands for TLR2/1 (Pam3CSK4),
TLR3 (Poly(I:C)) and TLR7/8 (R848). These experiments learned
that the inhibitory effect of ICs on TLR signaling by gmMQ is not
limited to TLR4, but also extends to TLR2/1, TLR3 and TLR7/
8 (Figure 2C), further substantiating the pivotal role of the FccR
balance in the regulation of cell activation. Again, IL-10
production by gmMQ was not clearly affected by the presence of
ICs and the inhibitory effect on TNFa production was not present
in mMQ (data not shown). To determine if ICs could also affect
TLR induced cytokine production after TLR stimulation has
already occurred, we performed a time course with addition of ICs
from 2 hours prior to Pam3CSK4 till 2 hours after Pam3CSK
stimulation. ICs were able to significantly modulate TNFa
production during the whole time range, without significantly
affecting IL-10 (data not shown). ICs can thus modulate TLR
induced cytokine production before and after TLR triggering.
Immune complexes can inhibit gmMQ activation by
activated T cells
Another important activator of RA synovial macrophages are
cytokine activated T cells. We therefore evaluated cytokine
production in co-cultures of Tck with gmMQ or mMQ. Tck
induced a synergistic production of TNFa when co-cultured with
gmMQ (Figure 3A), while IL-10 is almost absent, resulting in an
unbalanced proinflammatory response. The TNFa production by
mMQ after co-culture with Tck is much lower and not significantly
different from mMQ alone (Figure 3A). In contrast to mMQ
stimulation by TLR ligands, in co-culture with Tck also IL-10
production remained low. Thus, Tck mainly stimulate gmMQ. To
determine if ICs could inhibit Tck induced TNFa production
when macrophages express high FccRIIb levels, gmMQ were
stimulated with ICs and Tck. IC co-stimulation reduced the TNFa
release by gmMQ with approximately 50% upon Tck stimulation
(Figure 3B). ICs can thus modulate both TLR and T cell induced
gmMQ activation.
gmMQ Express Functionally High FccRIIb Levels
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The inhibitory effect of ICs is mediated via FccRIIb and
the PI3K pathway
To confirm whether the high FccRIIb expression on gmMQ
was indeed responsible for the inhibitory effect of ICs on TLR and
Tck induced signaling in these cells, we used a blocking antibody
against FccRIIb. Blocking of FccRIIb fully abrogated the
inhibitory effect of ICs on both TLR and Tck induced TNFa
production (Figure 4A and B).
In DCs our group has previously shown that the PI3K/Akt
pathway is involved in the crosstalk between FccRIIb and TLR4
[21]. To determine if this pathway is also involved in the FccRIIb
effect on macrophages, we blocked PI3K signaling before
stimulation of gmMQ with ICs and LPS. The IC mediated
inhibition of LPS induced TNFa production was abrogated in the
presence of Wortmannin or LY294002, confirming the role of the
PI3K pathway in FccRIIb mediated TLR4 signaling inhibition in
gmMQ (Figure 4C and data not shown). Mice studies pointed
towards an additional role for prostaglandin E2 in the inhibitory
actions of FccRIIb on TLR4 signaling [22]. To test this in the
human setting we performed our experiments in the presence of a
COX2 inhibitor. This did not affect the IC mediated inhibition of
cytokine production by gmMQ upon TLR4 stimulation (Fig-
ure 4C). To test if the same mechanism was involved in IC
mediated blocking of other TLRs we tested FccRIIb blocking and
PI3K inhibition also for ICs in combination with TLR2/1
stimulation and this gave similar results as shown for TLR4 (data
not shown).
To further determine if similar pathways are involved in
inhibition of Tck induced macrophage activation we performed
Figure 2. Immune complexes can inhibit TLR2, 3, 4 and 7/8 induced cytokine production in gmMQ. gmMQ and mMQ were stimulated
with ICs (50 mg/ml) (A), LPS (100 ng/ml) or LPS+ICs (B) and TNFa and IL-10 were measured in culture supernatants after 20 hours. (C) gmMQ were
stimulated with Pam3CSK4 (5 mg/ml), Poly(I:C) (25 mg/ml) or R848 (2 mg/ml) in the presence or absence of ICs. After 20 hours, supernatants were
collected and analyzed for TNFa levels. Figure shows data of at least 7 donors for all stimulations. *P,0.05 difference with and without IC.
doi:10.1371/journal.pone.0110966.g002
gmMQ Express Functionally High FccRIIb Levels
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Figure 3. IC can inhibit T cell mediated macrophage activation in gmMQ. gmMQ or mMQ and Tck were cultured from the same donor. (A) At
day 6 the macrophages and Tcks were harvested, washed and cultured together in a ratio of 1:5. TNFa and IL-10 were measured in the supernatant
after 20 hours. Bars are mean and SEM from 3 independent experiments. (B) gmMQ were cultured alone or in a 1:5 ratio with Tck in the presence or
absence of ICs (50 mg/ml) for 20 hours before collecting the supernatant. Bars are mean and SEM from 6 independent experiments. *P,0.05, NS is
not significant.
doi:10.1371/journal.pone.0110966.g003
Figure 4. TLR and Tck inhibition by IC is mediated via FccRIIb and PI3K. gmMQ were pre-incubated for 30 minutes with the FccRIIb specific
blocking antibody 2B6 (10 mg/ml) or an isotype control before stimulation with IC (50 mg/ml) and LPS (100 ng/ml) (A) or Tck (B). gmMQ were pre-
incubated with Wortmannin (0.1 mM) or a Cox2 inhibitor (20 mM) for 1 hr before stimulation with IC and LPS (C) or Tck (D). 20 hour supernatants
were collected to analyze TNFa levels. In the graphs showing TLR stimulation (A and C) the percentage of TNFa production is plotted with the LPS
only stimulation set at 100%. In the Tck graphs (B and D) absolute values are shown. All graphs show the mean and SEM of at least 3 experiments.
*P,0.05.
doi:10.1371/journal.pone.0110966.g004
gmMQ Express Functionally High FccRIIb Levels
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the Tck experiments in the presence of Wortmannin or a COX2
inhibitor. As for TLR activation a functioning PI3K pathway was
necessary for the inhibitory effect of ICs, however IC mediated
blocking of gmMQ activation via Tck also appeared to be
dependent on prostaglandin production, as is exemplified by the
lack of IC mediated inhibition in the presence of a COX2
inhibitor (Figure 4D). IC mediated inhibition of gmMQ TNFa
production via both pathways is mediated via binding to FccRIIb
and involves the PI3K pathway. Prostaglandins are necessary for
the effect of IC when combined with Tck, but not for TLR
mediated cell activation.
Discussion
The present study shows that gmMQ have a relatively high
expression of FccRIIb compared to the activating FccRs, while
this balance is shifted towards the activating FccRs on mMQ.
gmMQ secrete large amounts of TNFa upon stimulations relevant
in RA, such as TLR ligands and cytokine activated T cells. Under
these conditions inhibitory immune receptors, such as FccRIIb,
are crucial to counter-regulate the induced inflammatory respons-
es to prevent excessive tissue damage. We show that the switched
balance towards the inhibitory FccRIIb on gmMQ is functionally
relevant and can inhibit TNFa secretion from these cells induced
by either TLRs or Tck in the presence of soluble ICs. This way it
could function as a natural brake in an attempt to prevent
excessive cytokine production and inflammation in RA.
The important regulatory role of FccRIIb is extensively shown
in animal models for autoimmunity (Reviewed in [29]). In this
context it was shown that the transfer of RA but not healthy
control serum can induce arthritis in FccRIIb2/2, but not in
normal B6 mice [30]. This was caused by the IgG portion
supporting a pathogenic role for IgG (auto) antibodies from RA
patients and an important regulatory role for FccRIIb. This model
bypasses the effect of B cells because human IgG is passively
transferred and it thus shows that FccRIIb expression on other
effector cells, including macrophages and DCs, is crucial to
prevent autoimmune inflammation.
We demonstrated for the first time that FccRIIb can inhibit
cytokine induction by a wide range of TLRs, of which ligands have
been found in the arthritic joint, including TLR2, TLR3, TLR4
and TLR7/8. In addition, FccRIIb can also inhibit macrophage
TNFa production induced by activated T cells. This way FccRIIb
can actively control two important stimulatory pathways for
macrophages in RA. Inhibitor studies taught us that normal PI3K
signaling is necessary for FccRIIb inhibition of both TLR and Tck
induced cytokine release, while prostaglandins are only involved in
the latter. Prostaglandins were postulated as an essential signaling
molecule in FccRIIb mediated inhibition of TLR4 in mouse
macrophages [22]. However, in our human experimental setting
prostaglandins are dispensable for FccRIIb mediated inhibition of
TLRs. In our cultures prestimulation of gmMQ with ICs for only
15–30 minutes or up to 2 hours after TLR stimulation was enough
to get inhibition, while in mouse macrophages the dependency on
prostaglandins was demonstrated after 24 hour prestimulation
with ICs [22]. So prostaglandins are not necessary for the direct
inhibition of TLR4 signaling by FccRIIb in humans, but might
have additional inhibitory effects at later time points. This would
be in line with the dependency of Tck inhibition on prostaglandin
production, since the induction of TNFa in this setting is described
to be much slower (peaks at 24 hrs.) compared to TLR stimulated
TNFa induction (peaks at 4–8 hrs.) [31]. However, much is still
unknown about the pathways involved in macrophage activation
upon interaction with Tcks. CD69, CD18 and CD49d on the Tck
were shown to be involved in the induction of TNFa by monocytes
upon Tck co-culture [14]. On monocytes/macrophages ICAM-1
and VCAM-1 might be involved as binding partners for CD18
and CD49d, respectively. Thus far, no direct interactions are
known between these molecules and FccR signaling. Hence, our
work justifies more research focused at deciphering potential
mechanisms involved in FccRIIb inhibition on T cell mediated
macrophage activation.
Interestingly, the increased membrane FccRIIb expression on
gmMQ coincides with an increased expression of FccRIIb1 on
mRNA level. This suggests that FccRIIb1 expression on gmMQ
could play a role in the inhibitory effects of ICs on these cells.
Although the FccRIIb isoforms have been repeatedly shown to
have differential endocytosis potential [17–19], not much is known
about possible differences in inhibitory signaling. It has been
described that FccRIIb1 is differently phosphorylated in B cells
compared to FccRIIb2 and might have additional inhibitory
functions [19,32], but this has not been repeated by another group
in macrophage cell lines [33]. Whether this could have functional
implications for macrophage responses towards ICs needs to be
further investigated.
Some groups have tried to identify the macrophage phenotype
or the FccR expression on macrophages from RA synovial tissue.
FccRII overall, FccRIIb in particular and FccRIII were all
increased in RA synovium and correlated with the amount of
macrophages present [34,35]. Looking at in vitro markers for
gmMQ and mMQ it remains difficult to fully characterize the
macrophages from the synovial tissue since they express markers
representing both phenotypes [36,37]. Supported by our data the
expression of FccRIIb could be an additional marker for gmMQ
while FccRIII marks mMQ macrophages. The ratio between these
two FccRs could be a good discriminator between these
macrophage subsets. The high expression of activating FccRs by
mMQ, which are mainly described for their controlling/homeo-
static functions, and the high expression of the inhibitory FccRIIb
on the more inflammatory gmMQ might seem contradictory.
However, because of the easily activated phenotype of gmMQ
regulatory mechanisms including those via FccRIIb are crucial to
prevent excessive inflammation and tissue damage. In addition,
the capacity of mMQ to remove IC is facilitated by the high
expression of FccRs, preventing accumulation of IC and thereby
preventing unwanted inflammatory responses. Next to that we
show that small ICs in combination with TLR stimulation mainly
increase IL-10 production in mMQ and no major induction of
TNFa was observed.
The in vivo situation is not as black and white as shown by this
in vitro model, but knowledge about functional characteristics of
these macrophage subsets combined with more detailed pheno-
typing of local macrophages, including differentiation between
FccRIIa and FccRIIb in different diseases might give clues about
the pathogenic processes going on in vivo. This could possibly give
leads for therapeutic options to increase FccRIIb expression on
macrophages even further to induce a more inhibitory phenotype.
Conclusions
gmMQ and mMQ are characterized by a different FccR
balance, with high FccRIIa and FccRIII levels on mMQ and
increased FccRIIb expression on pro-inflammatory gmMQ. The
relatively high FccRIIb expression on gmMQ makes these cells
sensitive to IC mediated inhibition of proinflammatory cytokine
release upon stimulation by TLR ligands and Tck, which can be
an important feedback mechanism to prevent excessive inflam-
mation. This shows that FccRIIb mediated cell inhibition is not
gmMQ Express Functionally High FccRIIb Levels
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restricted to ITAM containing receptors or TLR4, but can
broadly regulate immune responses. Specific targeting of FccRIIb
might therefore open novel therapeutic avenues for RA and other
chronic immune mediated inflammatory disorders.
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